Kagaayi J., Makumbi F., Nakigozi G., Wawer M.J., Gray R.H., Serwadda D., Reynolds S.J.
Rakai Health Sciences Programme, Rakai, Uganda; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Institute of Public Health, Makerere University, Kampala, Uganda; National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; Johns Hopkins School of Medicine, Baltimore, MD, United States
Kagaayi, J., Rakai Health Sciences Programme, Rakai, Uganda; Makumbi, F., Rakai Health Sciences Programme, Rakai, Uganda; Nakigozi, G., Rakai Health Sciences Programme, Rakai, Uganda; Wawer, M.J., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Gray, R.H., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Serwadda, D., Institute of Public Health, Makerere University, Kampala, Uganda; Reynolds, S.J., National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States, Johns Hopkins School of Medicine, Baltimore, MD, United States
The ability of WHO clinical staging to predict CD4 cell counts of 200 cells/μl or less was evaluated among 1221 patients screened for antiretroviral therapy (ART). Sensitivity was 51% and specificity was 88%. The positive predictive value was 64% and the negative predictive value was 81%. Clinical criteria missed half the patients with CD4 cell counts of 200 cells/μl or less, highlighting the importance of CD4 cell measurements for the scale-up of ART provision in resource-limited settings. © 2007 Lippincott Williams & Wilkins, Inc.
adult; antiviral therapy; article; CD4 lymphocyte count; clinical assessment; clinical evaluation; controlled study; diagnostic accuracy; diagnostic value; female; human; major clinical study; male; prediction; priority journal; scale up; screening test; sensitivity and specificity; Uganda; world health organization; Anti-Retroviral Agents; CD4 Lymphocyte Count; HIV Infections; Humans; Rural Health; Sensitivity and Specificity; Uganda